Company Information

Company Profile

AngioGenex (Ticker: AGGX) is a biopharmaceutical company committed to the discovery and development of Id protein inhibitors to address unmet medical needs in oncology and ophthalmology. AngioGenex and its collaborators, including Robert Benezra, Ph.D., and The Robert Benezra Lab at Sloan Kettering Institute, have assembled key platform enabling technologies and tools that allow for the identification of specific and potent small molecule binders of Id. Id proteins have been shown to play a key role in mediating the pathogenesis of certain cancers and diseases of the eye. AngioGenex’s lead development candidate is AGX-A, a novel small molecule being investigated for the treatment of cholangiocarcinoma (a form of liver cancer) and age-related macular degeneration (AMD). AngioGenex is headquartered in New York, NY.

IR Contacts

Investor Relations
Michael Strange
(646) 642-0701

U.S. Legal Council
Cravath, Swaine & Moore LLP
825 Eighth Avenue
New York, NY 10019
(212) 474-1000

733 Third Avenue
New York, NY 10017
(212) 949-8700

Transfer Agent
NATCO Nevada Agency and Trust Co.
50 W Liberty Street, Suite 880
Reno, NV 89501
(775) 322-0626

Frequently Asked Questions

Can I buy stock directly from AngioGenex?
No, you will need to contact a licensed stock broker or use an online trading account

How do I get my purchased shares?
Contact NATCO Nevada Agency and Trust Co. at (775) 322-0626

Who can I contact for general information about AngioGenex?
Email us at

Where is AngioGenex headquartered?
425 Madison Avenue, Suite 902, New York, NY, 10017

When was AngioGenex incorporated?
AngioGenex was incorporated in the state of Nevada on April 1, 1999

When is AngioGenex’s fiscal year end?
December 31st

Who are AngioGenex’s independent auditors?

Who is AngioGenex’s outside legal counsel?
Cravath, Swaine & Moore LLP